All In Biotech

Drug Trial Radar · NCT04058587

A Phase I Trial of Simmitinib in Advanced Solid Tumors

Phase I Dose-escalation Trial of Simmitinib for Patients With Advanced Solid Tumors in Therapeutic Failure

Last checked: Nov 19, 2026Latest source record: Jun 6, 2022 (this record)Source: ClinicalTrials.govMethods & limitations

Status unknown

Status

Status unknown

Enrollment

50

Planned (sponsor's estimate)

Start

Jun 8, 2020

Primary completion

Jan 31, 2023

Study completion Mar 31, 2023

Sponsor

Sponsor type
Industry
Collaborators
Shanghai Runshi Pharmaceutical Technology Co., Ltd
First posted
Aug 15, 2019

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 70 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This is an open label, multi-center, phase I study of oral Simmitinib in subjects with advanced solid tumors including gastric cancer.

Conditions

  • Advanced Solid Tumor

Interventions

  • SimmitinibDrug

    The core trial period includes 4-weeks Screening stage (28d), 7-days single administration stage, 4-weeks multiple administration stage (28d), 3-days blood collection stage of PK after multiple administration. The starting dose was set at 1mg/d on toxicology data. Dosing will continue uninterrupted for 28 days in multiple administration stage. The dose-limiting toxicity (DLT) period assessment will be from the first administration of Simmitinib tablet to the end of the first cycle (35 days).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Dose-limited toxicity (DLT)Time frame: 1 year
  2. Maximum tolerated dose (MTD)Time frame: 1 year
  3. Recommended Phase II Dose (RP2D)Time frame: 1 year

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

    Beijing, China · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.